AA
TRVI icon

AlphaCentric Advisors’s Trevi Therapeutics TRVI Stock Holding History

AlphaCentric Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$454K Buy
24,317
+347
+1% +$5.05K 0.38% 95
2026
Q1 		$286K Buy
23,970
+1,303
+6% +$14.6K 0.29% 113
2025
Q4 		$284K Buy
+22,667
New +$262K 0.28% 113

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

AlphaCentric Advisors's TRVI Position: Q2 2026 in Review

AlphaCentric Advisors increased its Trevi Therapeutics (TRVI) stake by 1.4% in Q2 2026, buying an estimated $5.05K and bringing the position to 24,317 shares worth $454K. The position accounts for 0.38% of the portfolio, ranked #95.

AlphaCentric Advisors first reported a position in TRVI in Q4 2025 and has held it in 3 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • AlphaCentric Advisors held 24,317 shares of Trevi Therapeutics worth $454K as of Q2 2026.
  • AlphaCentric Advisors bought 347 Trevi Therapeutics shares in Q2 2026, an estimated $5.05K.
  • Trevi Therapeutics made up 0.38% of AlphaCentric Advisors's portfolio in Q2 2026, its #95 holding.
  • AlphaCentric Advisors first reported a position in Trevi Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.